GI Cancers | Clinical

Pembrolizumab Improves HRQoL in Patients with Metastatic MSI-H/dMMR Advance Noncolorectal Solid Tumors

July 01, 2021

Pembrolizumab monotherapy demonstrated improvement in health-related quality of life in patients with previously treated metastatic microsatellite instability-high/ mismatch repair deficient advanced noncolorectal solid tumors, with the biggest improvements seen in those who achieved a complete remission or partial remission.

Immune-Related End Points Consistent With Traditional Measurements of Dostarlimab in Non-Endometrial dMMR Solid Tumors

July 01, 2021

Dostarlimab achieved durable antitumor responses in patients with non-endometrial mismatch repair–deficient solid tumors treated in an expansion cohort of the phase 1 GARNET trial, according to interim findings presented during the ESMO World Congress on Gastrointestinal Cancer.